David M. Lucas, Ph.D.

Current Title: Research Assistant ProfessorDivision of Hematology, Department of Internal Medicine, College of MedicineDivision of Medicinal Chemistry & Pharmacognosy, College of PharmacyScientific Director, Leukemia Tissue Bank Shared Resource, The Ohio State

University Comprehensive Cancer Center (OSUCCC)The Ohio State University, Columbus Ohio

Contact: david.lucas@osumc.edu (614) 685-5667

Education:9/87 – 5/91 B.A., Chemistry, magna cum laude. Miami University, Oxford, Ohio9/91 – 9/96 Ph.D., Cell and Molecular Biology, University of Wisconsin, Madison10/96 – 2/00 Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center, Seattle,

Washington

Professional Experience:

3/14-present: Scientific Director, Leukemia Tissue Bank Shared Resource, OSUCCC

4/09-present: Research Assistant Professor, Division of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, OSU

1/08-present: Research Assistant Professor, Division of Hematology, Department of Internal Medicine, OSU. Responsibilities as below, plus expectations of obtaining individual grant support as a Principal Investigator, senior authorship on manuscripts, graduate student mentorship and independence in research projects.

12/02-12/07: Research Scientist and Director, Laboratories of Experimental Therapeutics, OSUCCC. Promotion to Research Scientist in the same position as below, plus additional supervisory and mentorship duties for laboratory personnel including graduate students and postdoctoral associates, as well as additional collaboration, grant writing, and manuscript writing and review duties.

3/00-12/02: Senior Research Associate and Director, Laboratories of Experimental Therapeutics, OSUCCC. Principal Investigators: John Byrd, M.D. and Michael Grever, M.D. Under the guidance of Drs. Grever and Byrd, scientific direction and supervision of research assistants and associates on: (1) Receiving, processing and performing cellular characterizations on samples from a multi-center Phase III clinical trial; (2) Plasma pharmacokinetic analysis of pentostatin in samples from patients on clinical trials; (3) Projects related to the identification and biological evaluation of novel therapies for Chronic Lymphocytic Leukemia. Had significant scientific input on each of the projects and was a key participant in the submission of funding applications and manuscript preparation. In addition to these projects, this position included laboratory management, hiring, training, and supervision of research assistants and associates, equipment and infrastructure setup and management, review of scientific manuscripts, and grant and budget administration.

Updated 4.09.2015

9/96-2/00: Postdoctoral Fellow, Fred Hutchinson Cancer Research Center, Seattle, Washington. Principal Investigator: Larry Rohrschneider, Ph.D. Project: To investigate the role of SH2 domain-containing Inositol Phospatase (SHIP) in Macrophage Colony Stimulating Factor (M-CSF) signaling in myeloid cells. Used protein expression, interaction, and phosphorylation analysis techniques as well as molecular techniques (Southern and Northern Blotting, RT-PCR, cDNA library screening and DNA sequencing) to investigate the role of SHIP and a novel SHIP isoform in M-CSF signaling. Identified and characterized a novel splice variant of SHIP and generated monoclonal antibodies that distinguish it from the normal form. Received a National Institutes of Health National Research Service Award (F32-DK09774, 5/1/98-1/31/00) to perform this work. This work also resulted in development of monoclonal anti-SHIP antibody P1C1, licensed to and now sold by Santa Cruz Biotechnology, Inc.

9/94-5/95: Teaching Assistant, Department of Medical Microbiology and Immunology, University of Wisconsin. Classes administered by Dean Manning, M.D. Assisted in a medical microbiology laboratory class for the University of Wisconsin Medical School (two semesters). Responsible for preparation of equipment, reagents, and supplies, verbal instruction and demonstration of medical microbiology laboratory techniques, providing group and individualized assistance to students, and proctoring and grading exams.

10/91-8/96: Graduate Research Associate, Department of Medical Microbiology and Immunology, University of Wisconsin, Madison. Graduate student under the mentorship of Donna Paulnock, PhD, and funded by a National Institutes of Health Training Grant in Cellular and Molecular Biology. Investigated the mechanism of interferon-mediated gene transcription in the process of macrophage activation for tumoricidal activity. Ph.D. awarded 8/96.

5/91-9/91: Laboratory Technician, Department of Chemistry, Miami University, Oxford Ohio, under the mentorship of Jan Jaworski, Ph.D., Professor of Chemistry, and funded by a Howard Hughes Institute award. Performed chromatographic purification and polyacrylamide gel electrophoresis characterization of the enzyme ketoacyl synthase III from cyanobacteria Anacystis nidulans. Used protein purification techniques including differential precipitation and concentration methods and standard and high-performance liquid chromatography. Target characterized by isotopic kinetic assays and SDS-PAGE gel electrophoresis.

9/90-5/91: Undergraduate research assistant, Miami University, Oxford Ohio, under the supervision of Susan Barnum Ph.D., Department of Botany, and Jan Jaworski Ph.D., Department of Chemistry. Propagated and cryopreserved stocks and lysates of cyanobacteria for enzyme studies. Also performed bacterial transformation, lambda virus and plasmid propagation, DNA purification, cloning and sequencing.

Updated 4.09.2015

Awards and Fellowships1987 Ben Suffron Memorial Scholarship (Miami University)

1987-1991 Miami Alumni Merit Scholarship (Miami University)

1987-1991 National Merit Scholarship

1990 Harvey Clayton Brill Scholarship in Chemistry (Miami University)

1991 Wisconsin Alumni Research Foundation Fellowship (University of Wisconsin)

1994 Presidential Awards Competition (Society of Leukocyte Biology)

1992-1995 Training Grant in Molecular Biology (National Institutes of Health)

1997-2000 National Research Service Award (F32, National Institutes of Health)

2004 V-Foundation-AACR Translational Grant Award (Co-Investigator)

2007 American Cancer Society Institutional Seed Grant recipient

2011 Pelotonia Idea Award Co-Recipient

Additional Activities2003-present Member, American Society of Hematology; American Association of Cancer

Research

2006-present Ad hoc reviewer: Blood, Journal of Natural Products, Journal of Clinical Oncology, Journal of Clinical Investigation, Leukemia, Leukemia Research, Leukemia & Lymphoma, Haematologica, European Journal of Hematology, British Journal of Haematology, PLoS One, PLoS Medicine, Blood Cancer Journal, ACS Chemical Biology

Teaching2014 (Fall) Teacher (team) – Divisions of Hematology & Medical Oncology, CRC & Basic

Science Education series, “Cell and Molecular Biology Techniques.” September 23, 2014

2014 (Spring) Teacher (team) – MCDB 7890/7891, Molecular, Cellular, and Developmental Biology, Student Seminar

AdvisingOSU Undergraduate Students (Research Advisor):2004 Benjamin Lampson2006 Rebekah Browning2009 David Caldwell2010 James Hall

OSU Graduate Students (co-advisor, committee member): 2007-2009 Yanhui Lu, College of Pharmacy, Division of Pharmaceutics2007-2012 Sneha Gupta, College of Pharmacy, Division of Pharmaceutics

Updated 4.09.2015

2010-2014 Lynette Bueno-Perez, College of Pharmacy, Division of Medicinal Chemistry & Pharmacognosy

2011-present John Patton, College of Veterinary Medicine2011-present Yo-Ting Tsai, College of Pharmacy, Division of Pharmaceutics

Post Doctoral (co-advisor)2007-2012 Erin Hertlein, Department of Internal Medicine, Division of Hematology

Current Research Funding

NCI 1 UM1 CA186712-01 (PI: Grever) 02/01/2014 – 01/31/2019 Experimental Therapeutics of Anti-Cancer Agents with Phase I EmphasisThis proposal seeks to continue hypothesis driven, disease or target specific Phase I trials of promising anticancer agents alone or in combination through the Experimental Therapeutics Program of the NCI Clinical Trials Network (ET-NCTN). The ultimate goal of this proposal is the development of the most effective (rather than the most toxic) dose and schedule of promising new anticancer agents for further therapeutic investigation in late phase clinical trials by the NCTN.Role: Co-Investigator

Leukemia & Lymphoma Society (Leader: Byrd) 10/2010 - 09/2015LLS 7004-11 Specialized Center of Research (SCOR) in CLLProject 5: Molecular Target-Based Therapeutics for Leukemia. The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high risk CLL. Role: Co-Investigator

NCI 2 P01 CA081534-14 (SubK PI:Johnson) 09/2012 – 08/2017Univ. of California at San Diego Chronic lymphocytic leukemia research consortium, Project 6.To investigate drug resistance in CLL and identify new therapeutic agents through participation in the consortium. Role: Co-Investigator

NCI 5 R01 CA183444-02 (PI: Byrd/Johnson/Woyach) 01/2014 – 13/2018Molecular Evaluation of Targeted Therapies in Lymphoid MalignanciesA Phase III clinical trial investigating ibrutinib alone or ibrutinib plus rituximab compared with standard therapy of bendamustine plus rituximab (BR) in older patients with previously untreaded CLL. Role: Co-Investigator

NCI 2 P01 CA125066-06 (PI: Kinghorn) 12/01/13-11/30/18 Discovery of Anticancer Agents of Diverse Natural OriginThe overall goal of this project is to discover novel chemicals from selected tropical rainforest plants, as well as cyanobacteria and fungi, for development as cancer chemotherapeutic agents, particularly for tumors not cured by present treatment methods. Role: Co-Investigator, Project 1

Updated 4.09.2015

NCI - ZC 5 P30 CA016058-39 (PI: Caligiuri)08/05/2011 – 11/30/2015

OSU Comprehensive Cancer Center Support Grant, Leukemia Tissue Bank.The overall goal of the OSUCCC is to reduce cancer morbidity and mortality through continued basic, translational and clinical research.Role: Co-Investigator (Director, Leukemia Tissue Bank Shared Resource)

Past Research Funding

NCI- Mayo Foundation 5 R01 CA095241-09 (PI: Byrd) 08/2008 - 05/2013B-Cell Biology: Impact of Combination TherapySpecific Aims: 1) To assess clinical efficacy and toxicity of pentostatin/cyclophosphamide plus rituximab for previously untreated CLL patients. 2) To correlate gene expression profiles of patients with laboratory parameters and clinical outcome. 3) To assess angiogenic profile of CLL cells and compare the profile to CLL cell apoptosis/resistance status and clinical response. 4) To determine association of clinical response with CLL cell resistance to stress-induced apoptosis and responsiveness to rituximab. Role: Co-Investigator

Leukemia & Lymphoma Society (LLS) 7080-06 SCOR (Leader: Byrd) 10/2005 - 09/2010SCOR: Experimental therapeutics in CLL.Project 1: Pre-Clinical and Clinical studies of Flavopiridol in CLL. The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high risk CLL. Role: Co-InvestigatorProject 2: Chromatin Remodeling as a Therapeutic Target to Enhance Biologic Therapies in CLL. The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high risk CLL. Role: Co-Investigator

NCI 2 P01 CA81534-06 (SubK PI: Grever) 06/2006 - 04/2011CLL Research Consortium (CRC). Project 6: Through participation in the consortium, to investigate drug resistance in CLL and identify new therapeutic agents. Role: Co-Investigator

NCI 5 P01 CA101956-03 (Leader: Jacob) 09/2006 - 07/2011 Project 1: DNA methylation & chromatin modifications: mechanisms & applications in cancer therapy. Clinical Investigation of Epigenetic Therapy. The overall goal is a translational program intended to gain insight into tumor-specific alterations in DNA methylation profile and chromatin configuration that can be therapeutically targeted in real time. Role: Co-Investigator Core C: DNA methylation & chromatin modifications: mechanisms & applications in cancer therapy - Pathology/Tissue Procurement. Role: Co-Investigator

OSUCCC Pelotonia Idea Grant (PIs: Byrd, Hai, Lucas) 10/2011 – 10/2012The Roles of ATF3, an Adaptive-Response Gene with Dichotomous Function, in the Development and Treatment of Chronic Lymphocytic Leukemia (CLL). Role: Co-Principal Investigator

Updated 4.09.2015

NCI R21CA156222 (PI: Hofmeister) 08/2011 – 07/2013Phase 1 of AR-42 in relapsed CLL, lymphoma, myeloma. Aim: To perform a first-in-man study of AR-42 in relapsed lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma patients. Role: Co-Investigator.

Updated 4.09.2015

P ublications (*indicates equal contribution)McDowell MA, Lucas DM, Nicolet C, Paulnock DM. Differential utilization of interferon-γ responsive elements in two maturationally distinct macrophage cell lines. J Immunol. 1995; 155(10):4933-8.

Lucas DM, Lokuta MA, McDowell MA, Doan JE, Paulnock DM. Analysis of the interferon-gamma signaling pathway in macrophages at different stages of maturation. J Immunol. 1998; 160(9):4337-42.

Lucas DM, Rohrschneider LR. A novel spliced form of SH2-containing inositol phosphatase SHIP is expressed during myeloid differentiation. Blood 1999; 93(6):1922-33.

March ME, Lucas DM, Aman MJ, Ravichandran KS. p135 src homology 2 domain-containing inositol 5-phosphatase SHIP can substitute for p145 SHIP in FcγRIIB1-mediated inhibitory signaling in B cells. J Biol Chem. 2000; 275(39):29960-7.

Wolf I, Lucas DM, Algate PA, Rohrschneider LR. Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110 kDa splice isoform, SHIP-δ. Genomics 2000; 69(1):104-12.

Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas DM, Grever MR. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol. 2001; 29(6):703-8.

Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas DM, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99(3):1038-43.

Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas DM, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101(2):425-432.

Byrd JC, Lucas DM, Mone A, Kitner JB, Drabick JJ, Grever MR. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood 2003; 101(11):4547-50.

Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with caspase-8-mediated apoptosis and downregulation of c-FLIP protein. Blood 2003; 102(2):652-8.

Bains SK, Mone A, Yun Tso J, Lucas DM, Byrd JC, Weiner GJ, Green JM. Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia 2003; 17(7):1357-65.

Pavletic SZ, Bociek RG, Foran JM, Rubocki RJ, Kuszynski CA, Wisecarver JL, Hatcher L, Lucas DM, Byrd JC, Grever MR, Joshi SS, Hardiman P, Smith LM, McGuire TR, Bierman PJ, Vose JM, Armitage JO, Talmadge JE. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation 2003; 76(5):877-81.

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas DM, Grever MR, Byrd JC. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103(9):3278-81.

Updated 4.09.2015

Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu T, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Research 2004; 64(7):2424-33.

Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas DM, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. G3139, a BCL-2 antisense oligonucleotide in AML. Ann Hematol. 2004;83 Suppl 1:S93-4.

Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR. The Histone Deacetylase Inhibitor MS-275 Induces Caspase-Dependent Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells. Leukemia 2004; 18(7):1207-14.

Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105(3):959-67.

Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005; 23(17):3877-85.

Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005; 23(12):2661-8.

Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005; 19(7):1207-10.

Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006; 24(3):437-43.

Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108(4):1334-8.

Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109(2):399-404.

Su X, Jacob NK, Amunugama R, Lucas DM, Knapp AR, Ren C, Davis ME, Marcucci G, Parthun MR, Byrd JC, Fishel R, Freitas MA. Liquid chromatography mass spectrometry profiling of histones. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850(1-2):440-54.

Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007; 25(7):799-804.

Updated 4.09.2015

Su X, Zhang L, Lucas DM, Davis ME, Knapp AR, Green-Church KB, Marcucci G, Parthun MR, Byrd JC, Freitas MA. Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. Anal Biochem. 2007; 363(1):22-34.

Knapp AR, Ren C, Su X, Lucas DM, Byrd JC, Freitas MA, Parthun MR. Quantitative profiling of histone post-translational modifications by stable isotope labeling. Methods. 2007; 41(3):312-9.

Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM*, Byrd JC*. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007; 13(7):2144-50.

Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007; 13(8):2392-9.

Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007; 129(5):879-90.

Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, Byrd JC, Grever M, Jacob ST. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res. 2007; 13(11):3174-81.

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC*, Lucas DM*. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research 2007; 31(12):1737-40.

Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2007; 139(5):837-44.

Hussain SR*, Lucas DM*, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111(6):3190-9.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST. PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells. J Biol Chem. 2009; 284(1):455-64.

Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009; 113(3):535-7.

Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009; 23(5):912.

Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. Prolonged myelosuppression with clofarabine in the

Updated 4.09.2015

treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50(3):349-356

Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA. Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. Proteomics 2009; 9(5):1197-1206

Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113:4656-4666

Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 2009; 147(4):507-14.

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC. Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50(12):1977-82.

Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009; 1(1):31-40.

Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010; 66(1):151-8.

Sanchez-Aguilera A, Rattmann I, Drew DZ, Müller LU, Summey V, Lucas DM, Byrd JC, Croce CM, Gu Y, Cancelas JA, Johnston P, Moritz T, Williams DA. Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia 2010; 24(1)97-104.

Flynn JM, Andritsos L, Lucas DM, Byrd JC. Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. Br J Haematol. 2010; 149(3):388-90.

Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol. 2010; 150(2):189-95.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 2010; 95(7):1098-105

Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen C-S, Baiocchi RA, Byrd JC. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS ONE 2010; 5(6):e10941.

Updated 4.09.2015

Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010, 116:2554-2558.

Blum KA, Jung S-H, Johnson JL, Lin TS, His ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL, and for the Cancer and Leukemia Group B. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism Ann. Oncology 2010; 21:2246-2254.

Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 2011; 117:862-87.

Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA, Chan KK. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J. 2011; 13(3):347-56.

Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, Phelps MA, Grever MR, Lucas DM. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 2011; 13(3):357-64.

You J, Wang L, Saji M, Olesik SV, Ringel MD, Lucas DM, Byrd JC, Freitas MA.High-sensitivity TFA-free LC-MS for profiling histones. Proteomics 2011; 11(16):3326-34.

Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC, Croce CM, Jacob ST. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011; 118(23):6132-40.

Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. J Clin Oncol. 2012 Jul 10;30(20):2483-91.

Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell. 2012; 21(5):694-708.

Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. Leuk Lymphoma. 2012; 53(9):1743-8.

Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012; 120(6):1262-73

Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA*, Lucas DM*. Dual targeting of the cyclin/Rb/E2F and

Updated 4.09.2015

mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin Cancer Res. 2012; 18(17): 4600-11

Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas DM, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Selective inhibitors of nuclear export (SINE) show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012;120(23):4621-34.

Bueno Pérez L, Pan L, Sass E, Gupta SV, Lehman A, Kinghorn AD, Lucas DM. Potentiating Effect of the Flavonolignan (-)-Hydnocarpin in Combination with Vincristine in a Sensitive and P-gp-Expressing Acute Lymphoblastic Leukemia Cell Line. Phytother Res. 2013; 27(11):1735-8

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol. 2013; 6:21

Gupta SV, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, Davis ME, Woyach JA, Lehman A, Jarjoura D, Byrd JC, Lucas DM. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kB response in chronic lymphocytic leukemia cells. Clin. Cancer Res. 2013; 19:2406-2419

Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. Clin Pharmacokinet. 2013; 52(8):705-12

Bueno Pérez L, Li J, Lantvit DD, Pan L, Ninh TN, Chai HB, Soejarto DD, Swanson SM, Lucas DM, Kinghorn AD. Bioactive Constituents of Indigofera spicata. J Nat Prod. 2013; 76(8):1498-504

Singh R, Mortazavi A, Telu KY, Nagarajan P, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MR. Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis. Nucleic Acids Res. 2013; 41:9284-9295 Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS ONE. 2013; 8(9):e76136.

Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CT. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014; 28(10):1960-8

Woyach JA, Smucker K, Smith LL, Lonzanski A, Zhong Y, Ruppert AS, Lucas DM, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones JA, Flynn JM, Maddocks K, O’Brien S, Furman RR, James DF, Clob F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014; 123(12):1810-7.

Claus R*, Lucas DM*, Ruppert AS*, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014; 124(1):42-8.

Updated 4.09.2015

El-Elimat T, Raja HA, Figueroa M, Swanson SM, Falkinham Iii JO, Lucas DM, Grever MR, Wani MC, Pearce CJ, Oberlies NH. Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album. J Antibiot. 2014 Sep 24 [Epub ahead of print]

Andritsos LA, Dunavin N, Lozanski G, Jones JA, Blachly JS, Lucas DM, Byrd JC, Kraut E, Grever MR. Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. Haematologica. 2015; 100(1):e18-20

Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM*, Baiocchi RA*. The Translation Inhibitor Silvestrol Exhibits Direct Anti-Tumor Activity while Preserving Innate and Adaptive Immunity against EBV-Driven Lymphoproliferative Disease. Oncotarget. 2015; 6(5):2693-708

Blachly JS, Lozanski G, Lucas DM, Grever MR, Kendra K, Andritsos LA. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. J Natl Compr Canc Netw. 2015; 13(1):9-13

Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015 Mar 11:1-7. [Epub ahead of print]

Lucas DM*, Ruppert AS*, Lozanski G*, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR. Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-Term Follow-Up Study of the U.S. Intergroup Phase III Trial E2997. Leuk Lymphoma. 2015 Feb 27:1-24. [Epub ahead of print]

Updated 4.09.2015

Recent PresentationsNCI Translational Science Meeting: “The Protein Synthesis Inhibitor Silvestrol has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies”. Washington, DC, June 28, 2011

Comparative Oncology Program, The Ohio State University, Columbus, Ohio. “Silvestrol: Targeting Translation Initiation in B-cell Malignancies”. October 12, 2012

Chemistry Biology Consortium, “Silvestrol, A Plant-Derived Product with Potential as an Anti-Cancer Agent (NExt Development Project), Rockville, MD, February 6, 2014

Chronic Lymphocytic Leukemia Research Consortium (CRC) “ZAP70 Methylation”, San Diego, CA, April 25, 2014

German Cancer Research Center (DKFZ), Division of Molecular Genetics, “Direct and Immunomodulatory Effects of Silvestrol.” Heidelberg, Germany, June 25, 2014

Conducting Research with Biorepositories: Tools of the Trade: Using Biorepositories in research. The Ohio State University, Columbus Ohio, October 15, 2014

Malignant Lymphoma Retreat, German Lymphoma Research Group, “Lymphoma Drug Development at Ohio State University.” Heidelberg Germany, October 24, 2014

Society Pennies for Patients Presentations: Indianola Informal School, Columbus, Ohio, February 17, 2012 Buckeye Valley Middle School, Delaware, Ohio, February 21, 2012 Worthington Kilbourne Middle School, Worthington, Ohio, November 29, 2012 Westerville Central High School, Westerville, Ohio, March 11, 2013 Grove City Christian School, Grove City, Ohio, October 7, 2013 Granville High School, Granville, Ohio, November 22, 2013 Scottwood Elementary, Columbus, Ohio, January 21, 2014 New Albany Middle School, New Albany, Ohio, January 27, 2014 St. Patrick Elementary School, London, Ohio, January 29, 2014 Genoa Middle School, Westerville, Ohio March 6, 2015

Services (Administrative, Committees & other)a.) Service to OSU Student and Other Local Organizations

The Ohio State University, Poster Judge, OSUWMC Trainee Research Day (April, 2014)

Meeting AbstractsMarcucci G, Bloomfield CD, Balcerzak SP, Korlas PJ, Stanley HR, Fingert H, Maghraby, EA, Lucas DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA. Phase I Trial of Genasense (G3139, Genta, Inc.), A BCL-2 Antisense, in Refractory or relapsed Acute Leukemia. Blood 96:513a, 2000

Bannerji R, Flinn IW, Pearson M, Shinn C, Sickler J, Lucas M, Lucas DM, Byrd JC. Campath-1H Antibody Induces Transmembrane Signaling in Vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance via a Caspase-9 Apoptotic Pathway. Program/Proceedings American Society of Clinical Oncology 1215a, 2001.

Updated 4.09.2015

Aron JL, Murphy T, Parthun MR, Bannerji R, Kanakry C, Lucas DM, Flinn IW, Marcucci G, Grever MR, Byrd JC. The Histone Deacetylase Inhibitor Depsipeptide (FR901228) Induces Apoptosis Via Activation of the Caspase 8 Pathway Concurrent with Lysine Specific Acetylation in Chronic Lymphocytic Leukemia Cells. Blood 98:11 807a, 2001.

Bannerji R, Kitada S, Flinn IW, Pearson M, Lucas DM, Grever MR, Reed JC, Byrd JC. Campath-1H Antibody Induces Transmembrane Signaling in vitro and in vivo in Patients with Chronic Lymphocytic Leukemia and Promotes Tumor Clearance in Part Through Caspase mediated Apoptosis. Blood 98:11 808a, 2001.

Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas DM, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA. Clinical and Biological Activity of Genasense (G3139, Genta, Inc.), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia: A Phase I Study. Blood 98(11):216b, 2001.

Baird ME, Lucas DM, Mone AP, Waymer S, Warrell RP, Byrd JC, Grever MR. G3139 Promotes Release of IL-8 by Chronic Lymphocytic Leukemia Cells Cultured in vitro: Potential Implications for Therapeutic Use. Blood 98(11):281b, 2001.

Lucas DM, Baird ME, Neuberg DS, Tallman MS, Flinn IW, Byrd JC, Grever MR. Importance of Culture Conditions for in vitro Chemosensitivity Assessment in Chronic Lymphocytic Leukemia Cells: Preliminary Results From Laboratory Studies, Eastern Cooperative Oncology Group Study 2997. Blood 98(11):284b, 2001.

Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Kourlas P, Lucas DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA. Biologic Activity of G3139 (Genasense), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia. American Society of Clinical Oncology 20:288a 1149, 2001.

Lucas DM, Parthun MR, Mojica RD, Mone AP, Byrd JC, Grever MR. MS-275 Reduces Viability and Induces Changes in Histone Acetylaton in Cells From Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL). American Association for Cancer Research 93rd Annual Meeting Program, 2002.

Lucas DM, Davis ME, Parthun MR, Mojica RC, Mone AP, Zwiesler J, Byrd JC, Grever MR. MS-275 Promotes Apoptosis in Cells from Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Concurrent with Inhibition of Histone Deactylase. Blood 100(11):1500a, 2002.

Dewald GW, Paietta E, Goloubeva O, Bennett JM, Brockman SR, Paternoster SF, Lucas DM, Neuberg DS, Flinn I, Tallman M, Grever MR, Byrd JC. Correlation of Interphase Fluorescence In Situ Hybridization (FISH) Anomalies with Cell Morphology and Immunophenotyping in Chronic Lymphocytic Leukemia (B-CLL). Blood 100(11): 2334a, 2002.

Lucas DM, Baird ME, Byrd JC, Tschumper RC, Jelinek DF, Kitada S, Reed JC, Rosenwald A, Staudt LM, Neuberg DS, Tallman MS, Flinn IW, Grever MR. ZAP70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin VH Gene Mutational Status in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL). Blood 100(11): 1478a, 2002.

Lin TS, Flinn IW, Lucas MS, Sickler J, Moran ME, Porcu P, Lucas DM, Grever MR, Byrd JC. Filgrastim and Alemtuzumab (Campath-1H) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia. Blood 100(11):3168a, 2002.

Mone AP, Lucas DM, Aron JL, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green Je, Grever MR, Byrd JC. HU1D10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia Cells: Justification for Combination Studies of Hu1D10 with P13 Kinase Inhibitors. Blood 100(11):1496a, 2002.

Updated 4.09.2015

Pavletic SZ, Bociek G, Foran, J, Hatcher L, Rubocki R, Kuszynsky, C, Lucas DM, Grever MR, Hock L, Joshi S. Hardiman P, Bierman P, Vose J, Armitage J, Talmage J. Immunological Effects of Pentostatin in a Minimally Myelosuppressive Regimen for Allogeneic Stem Cell Transplantation. Blood 100(11):2446a, 2002.

Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC. Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL). Blood 102(11):1594a, 2003.

Lucas DM, Zhang L, Freitas MA, Wickham J, Parthun MR, Davis ME, Marcucci G, Byrd JC, Grever MR. MS-275 Mediated Apoptosis and Generation of Reactive Oxygen Species Are Caspase Dependent in B-Cell Chronic Lymphocytic Leukemia (CLL). Blood 102(11):1566a, 2003.

Marcucci G, Stock W, Zwiebel JA, Cataland SR, Dai F, Moran M, Lucas DM, Liu S, Klisovic MI, Kefauver C, Green M, Chan KK, Frankel SR, Grever MR, Byrd JC. Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML). Blood 102 (11):1398a, 2003.

Marcucci G, Dai G, Klisovic MI, Shen T, Liu S, Sher DA, Lucas DM, Whitman SP, Vukosavljevic T, Zwiebel JA, Frankel SR, Grever MR, Stock W, Chan KK, Byrd JC.  Pharmacologic and Biologic Assessment of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML). Blood 102(11):3254a, 2003.

Grever MR, Lucas DM, Dewald GW, Neuberg DS, Flinn IW, Tallman MS, Gribben JG, Byrd JC. Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997. Blood 104:3487a, 2004.

Lin TS, Biswas S, Naumovski L, Lecane P, Lucas MS, Moran ME, Mone AP, Lucas DM, Phan S-C, Miller RA, Byrd, JC. Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL). Blood 104:3486a, 2004.

Lin TS, Heerema NA, Swenor J, Lucas MS, Moran ME, Cheney CM, Lucas DM, Young D, Caligiuri MA, Grever MR, Byrd JC. A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities. Blood 104:3469a, 2004.

Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran ME, Blum KA, Shank RS, Lucas DM, Lucas MS, Suarez J-R, Grever MR. Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL). Blood 104:341a, 2004.

Lin TS, Fischer B, Moran ME, Lucas DM, Shank RS, Kraut EH, Farag SS, Lucas MS, Colevas AD, Grever MR, Byrd JC. Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma. Blood 104:2492a, 2004.

Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas DM, Larson RA, Caligiuri MA, Heerema NA. Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy. Blood 104:476a, 2004.

Motiwala T, Ghoshal K, Majumder S, Kutay H, Neuberg DS, Kitada S, Reed JC, Dewald GW, Flinn IW, Tallman MA, Liu T, Plass C, Lucas DM, Byrd JC, Jacob ST, Grever MR. Methylation of

Updated 4.09.2015

the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL). Blood 104:2804a, 2004.

Lucas DM, Zhang L, Davis ME, Su X, Sklenar A, Parthun MR, Freitas MA, Kitada S, Reed JC, Marcucci G, Grever MR, Byrd JC. The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2. Blood 104:2802a, 2004.

Kitada S, Reed JC, Lucas DM, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Tallman MS, Byrd JC, Michael R. Grever MR. Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment. Blood 104: 956a, 2004.

Lucas DM, Dewald GW, Neuberg DS, Byrd JC, Lozanski G, Harbison J, Cunningham KD, Flinn IW, Tallman MS, Grever MR. Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used. Blood 104:949a, 2004.

Johnson AJ, Edwards R, Smith LL, Lucas DM, Croce CM, Muthusamy N, Chen C-S, Liu Z, Chan KK, Grever MR, Byrd JC. The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia. Blood 106:51a, 2005.

Johnson AJ, Wagner AJ, Smith LL, Lucas DM, DeLay MD, Allison JM, Ivy SP, Lin TS, Byrd JC.The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL. Blood 108:2101a, 2006.

Lucas DM, Hussain S-R A, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SK, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR. Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells. Blood 108:2098a, 2006.

Lin TS, Lucas MS, Heerema NA, Matkovich JA, Moran ME, Cheney C, Lucas DM, Young DC, Caligiuri MA, Grever MR, Byrd JC. A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities. Blood 108:2841a, 2006.

Edwards RB, Lucas DM, Lozanski G, Johnson AJ, Su B-N, Lin TS, Byrd JC, Kinghorn AD, Grever MR. Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells. Blood 108:2600a, 2006.

West DA, Lucas DM, Davis ME, DeLay MD, Johnson AJ, Guster SK, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, Byrd JC. The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia. Blood 108:2101a, 2007.

Browning RE, Lucas DM, Geyer SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC. Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia. Blood 108:2792a, 2006.

Lucas DM, Edwards RB, DeLay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD, Grever MR. The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL. Blood 110:3123a, 2007.

Updated 4.09.2015

DeLay MD, Johnson AJ, Lucas DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR, Byrd JC. Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia. Blood 110:3095a, 2007.

Alinari L, Hertlein E, Goldenberg DM, Lapalombella R, Yan F, Zhang X, Lucas DM, Muthusamy N, Byrd JC, Baiocchi RA. Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma. Blood 112: 886a, 2008.

Blum KA, Liu Z, Lucas DM, Baiocchi RA, Lin TS, Benson D, Devine SM, Jones J, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC. A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. Blood 112: 3169a, 2008.

Hertlein E, West DA, Craig RW, Lucas DM, Byrd JC. NF- B Is Active in Mcl-1 Promoter Regulation in Human CLL. Blood 112: 2265a, 2008.

Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC. The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia. Blood 114:886a, 2009.

Lucas DM, Sass EJ, Edwards RB, Pan L, Lozanski G, Heerema NA, Byrd JC, Kinghorn AD, Grever MR. Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression. Blood 114:1737a, 2009.

Hertlein E, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC. Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells. Blood 114:721a, 2009.

Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones JA, Flynn JM, Lucas DM, Grever MR, Byrd JC. Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol. Blood 116:691a, 2010.

Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR, Rowe JM, Lucas DM, Kitada S, Jelinek DF, Gribben JG, Byrd JC, Reed JC, Hussein MA, Appelbaum FR, Larson RA, Moore Jr DF, Tallman MS. Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. Blood 116:924a, 2010.

Hertlein EK, Yu L, Zhang J, Johnson AJ, Lucas DM, Marcucci G, Jarjoura D, Byrd JC. Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease. Blood 116:3642a, 2010.

Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, Garzon R, Lucas DM, Perrotti D, Wu L-C, Grever MR, Kinghorn AD, Marcucci G. The Natural Product Silvestrol Decreases Oncogenic FLT3 and miR-155 Levels in TLT3-ITD Positive Acute Myeloid Leukemia (AML) cells. Cancer Research 2010 70:3558.

Lucas DM, Alinari L, Patton J, Kinghorn AD, Baiocchi RA, Grever MR. “The Protein Synthesis Inhibitor Silvestrol has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies”, NCI Translational Science Meeting, Washington, DC, June 28, 2011.

Updated 4.09.2015

Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Chan KK, Kinghorn AD, Grever MR, Phelps MA, Lucas DM. Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin. Cancer Research 2011 71:1721.

Alinari L, Edwards RB, Prince CJ, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas DM. Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol. Blood (ASH Annual Meeting Abstracts). 2011; 118:3498

Gupta SV, Hertlein EK, Woyach JA, Sass EJ, Davis ME, Byrd JC, Lucas DM. The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF- B Response. Blood (ASH Annual Meeting Abstracts). 2011; 118:3510

Alachkar H, Santhanam R, Lucas DM, Schwind S, Hickey C, Pang J, Perrotti D, Pan L, Kinghorn AD, Marcucci G, Grever MR.  Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts). 2011; 118:2616

Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas DM, Grever MR, Baiocchi RA. Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity. Blood (ASH Annual Meeting Abstracts). 2011; 118:104 (Oral Presentation)

Claus R, Ruppert AS, Lucas DM, Zucknick M, Rassenti LZ, Greaves A, Neuberg DC, Wierda WG, Keating MJ, Brown JR, Gribben JG, Rai KR, Grever MR, Kay NE, Kipps MJ, Plass C, Byrd JC. The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood (ASH Annual Meeting Abstracts). 2012; 120:3865. 

Hertlein EK, Chen TL, Claus R, Plass C, Lehman A, Jarjoura D, Maddocks K, Jones JA, Lucas DM, . Johnson AJ, Byrd JC. The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2012; 120:1362.

Woyach JA, Flynn JM, Jones JA, Andritsos LA, Lucas M, Chase W, Yang Y, Lucas DM, Sass E, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC.  Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). (ASCO Meeting Abstracts). 2013; 31:7077. 

Patton JT, Hartlage AS, Pan L, Lustberg ME, Drohan CM, Martin MF, Kinghorn AD, Caligiuri MA, Grever MR, Lucas DM , Baiocchi RA. Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response To Epstein-Barr Virus-Driven Lymphoproliferative Disease. Blood. (ASH Annual Meeting Abstracts) 2013; 122:4422.